EL7.AI
StocksUpdated•Originally published 23 June 2026•Updated 23 June 2026•
2 min read

DexCom Stock Gains Momentum on Landmark FDA Pediatric Clearance and Deutsche Bank Buy Rating

Key Facts

1Deutsche Bank initiated coverage on Insulet with a Buy rating and a $190 price target, stating the stock is undervalued.
2Deutsche Bank assigned a Buy rating to DexCom with an $86 price target, expecting covered lives to double by 2027.

In a move strengthening its position in the home healthcare market, the U.S. Food and Drug Administration (FDA) has expanded the clearance of DexCom's Stelo Glucose Biosensor System for over-the-counter use in children aged two and older, marking a historic first for pediatric glucose monitoring. This regulatory milestone coincides with Deutsche Bank initiating coverage on DexCom and Insulet with Buy ratings, setting price targets of $86 and $190 respectively, citing significant undervaluation in the current market.

This regulatory expansion underscores DexCom's ability to penetrate new demographics, following a strong Q1 2024 performance where the company reported $1.0 billion in revenue, a 24% year-over-year increase according to company filings. While market data shows Abbott Laboratories remains a formidable peer in the continuous glucose monitoring space, DexCom's new over-the-counter (OTC) pediatric advantage provides a strategic edge in direct-to-consumer access, supporting the analyst view that prior selling pressure has likely bottomed out.

Regarding price action, DXCM is currently trading at $69.07 (close June 22, 2026), implying that Deutsche Bank's $86 target offers a potential upside of 24.5%. Investors should keep a close watch on upcoming US economic catalysts, including inflation data and retail sales, as well as further regulatory updates regarding insurance reimbursement for OTC monitoring devices which could further accelerate market adoption.